Sarepta Therapeutics drug testing plan for eteplirsen could help Duchenne's patient Ryan Dunne

DENVER - A local family is celebrating the news that a prescription drug company will push forward for a larger study for the Muscular Dystrophy drug eteplirsen.

Ryan Dunne is nine. He has Duchenne Muscular Dystrophy.

In March, more than 100,000 Coloradans and people across the country signed a petition on urging the Food and Drug Administration to use the Accelerated Approval pathway for approval and access to safe, effective therapies for Duchenne Muscular Dystrophy.

Monday, Massachusetts-based Sarepta Therapeutics said it plans to file a new drug application with the FDA and will push forward with a larger “confirmatory” study that will allow more boys access to eteplirsen and give regulators more robust data about its safety and effectiveness, according to the Washington Post.

Print this article Back to Top